Advancing from Precision Medicine towards Prevention in Parkinson’s disease
In 2015, the Luxembourg research community launched an ambitious initiative to transform the landscape of Parkinson’s disease research: the National Centre for Excellence in Research on Parkinson’s Disease (NCER-PD), initially funded by the Luxembourg National Research Fund (FNR).
In 2025, the NCER-PD celebrates a decade of science, clinical innovation, and close collaborations with people living with the disease, as well as the people that support them and the wider community.
Over the past 10 years, NCER-PD has united Luxembourg’s top research institutions, including the Luxembourg Institute of Health (LIH), the Luxembourg Centre for Systems Biomedicine (LCSB), the Integrated BioBank of Luxembourg (IBBL), and the Centre Hospitalier de Luxembourg (CHL). Together, they have built one of Europe’s most comprehensive Parkinson’s cohorts, developed new biomarkers for early diagnosis, and uncovered insights into mechanisms of neurodegeneration in Parkinson’s.
This 10-year anniversary is not just a celebration of scientific milestones, but a tribute to the hundreds of study participants, researchers, and healthcare professionals whose continuous contributions make progress possible. As we look to the future, NCER-PD remains committed to pushing the boundaries in precision medicine, digital phenotyping, and personalised care, up into first nation-wide precision prevention programmes, always keeping needs of patients at the heart of what NCER-PD does.